Instrument Inactif

Communiqués Amicus Therapeutics, Inc. London S.E.

Actions

0HF9

US03152W1099

Recherche biotechnologique et médicale

Communiqués

09/03	US Senate Probes FDA Bureaucracy vs. Innovation	AQ
23/02	Amicus Therapeutics: Q4 Earnings Snapshot	AQ
20/02	Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates	AQ
03/02	Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026	AQ
09/01	Amicus Therapeutics : Legend (1)	PU
26/12	Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, Inc. - FOLD	BU
19/12	BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook	PR
17/12	Amicus Therapeutics Announces Recipients of Inaugural Funding Programme for the Pompe Disease Community	BU
04/11	Amicus Therapeutics: Q3 Earnings Snapshot	AQ
04/11	Amicus Therapeutics : 3Q25 Earnings Deck FINAL	PU
04/11	Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates	AQ
03/11	Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025	AQ
31/10/25	Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025	AQ
23/10/25	Amicus Therapeutics to Announce Third Quarter 2025 Financial Results on November 4, 2025	AQ
08/09/25	New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM	AQ
29/08/25	Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025	AQ
06/08/25	Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators	PR
31/07/25	Amicus Therapeutics : 2Q25 Earnings Deck FINAL	PU
31/07/25	Amicus Therapeutics: Q2 Earnings Snapshot	AQ
31/07/25	Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates	AQ
21/07/25	Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025	AQ
25/06/25	Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan	AQ
04/06/25	Amicus Therapeutics - New Analysis of Pombiliti + Opfolda Published in Muscle and Nerve	AQ
03/06/25	New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve	AQ
30/05/25	Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025	AQ